Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-
1) infection has reached pandemic proportions. Forty years later, research has led to the …

Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …

Background Phase 3 clinical studies showed non-inferiority of long-acting intramuscular
cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important …

Background Long-acting injectable regimens may simplify therapy for patients with human
immunodeficiency virus type 1 (HIV-1) infection. Methods We conducted a phase 3 …

Importance Data on the use of antiretroviral drugs, including new drugs and formulations, for
the treatment and prevention of HIV infection continue to guide optimal practices. Objective …

Background Long-acting injectable antiretroviral therapy (LAI-ART) is approved for treatment-
naive or experienced people with human immunodeficiency virus (HIV; PWH) based on …

Background Previously reported post hoc multivariable analyses exploring predictors of
confirmed virologic failure (CVF) with cabotegravir+ rilpivirine long-acting (CAB+ RPV LA) …

Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed
intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here …

Background There is a need for more convenient, less frequent treatment to help address
challenges associated with daily oral HIV treatment in people living with HIV, including …